scholarly journals Development of High-Specific Activity and No-Carrier-Added Tin-117m for Radionuclide Therapy of Cancer

2009 ◽  
Author(s):  
Suresh Srivastava ◽  
Michael Furey
Keyword(s):  
Radionuclide Therapy ◽  
Specific Activity ◽  
High Specific Activity ◽  
No Carrier Added

scholarly journals Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

2021 ◽  
Vol 8 ◽  
Author(s):  
Michiel Van de Voorde ◽  
Charlotte Duchemin ◽  
Reinhard Heinke ◽  
Laura Lambert ◽  
Eric Chevallay ◽  
...  
Keyword(s):  
Neutron Irradiation ◽  
Radionuclide Therapy ◽  
High Efficiency ◽  
Separation Efficiency ◽  
Specific Activity ◽  
High Specific Activity ◽  
Mass Separation ◽  
Full Potential ◽  
Targeted Radionuclide Therapy ◽  
Very High

Samarium-153 (153Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics. 153Sm has a half-life of 1.93 d and decays into a stable daughter nuclide (153Eu) whereupon β− particles [E = 705 keV (30%), 635 keV (50%)] are emitted which are suitable for therapy. 153Sm also emits γ photons [103 keV (28%)] allowing for SPECT imaging, which is of value in theranostics. However, the full potential of 153Sm in nuclear medicine is currently not being exploited because of the radionuclide's limited specific activity due to its carrier added production route. In this work a new production method was developed to produce 153Sm with higher specific activity, allowing for its potential use in targeted radionuclide therapy. 153Sm was efficiently produced via neutron irradiation of a highly enriched 152Sm target (98.7% enriched, σth = 206 b) in the BR2 reactor at SCK CEN. Irradiated target materials were shipped to CERN-MEDICIS, where 153Sm was isolated from the 152Sm target via mass separation (MS) in combination with laser resonance enhanced ionization to drastically increase the specific activity. The specific activity obtained was 1.87 TBq/mg (≈ 265 times higher after the end of irradiation in BR2 + cooling). An overall mass separation efficiency of 4.5% was reached on average for all mass separations. Further radiochemical purification steps were developed at SCK CEN to recover the 153Sm from the MS target to yield a solution ready for radiolabeling. Each step of the radiochemical process was fully analyzed and characterized for further optimization resulting in a high efficiency (overall recovery: 84%). The obtained high specific activity (HSA) 153Sm was then used in radiolabeling experiments with different concentrations of 4-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA). Even at low concentrations of p-SCN-Bn-DOTA, radiolabeling of 0.5 MBq of HSA 153Sm was found to be efficient. In this proof-of-concept study, we demonstrated the potential to combine neutron irradiation with mass separation to supply high specific activity 153Sm. Using this process, 153SmCl3 suitable for radiolabeling, was produced with a very high specific activity allowing application of 153Sm in targeted radionuclide therapy. Further studies to incorporate 153Sm in radiopharmaceuticals for targeted radionuclide therapy are ongoing.

Irradiation methods for production of high specific activity radionuclides in no carrier added form

1995 ◽  
Vol 195 (2) ◽  
pp. 227-236 ◽  
Author(s):  
M. Bonardi ◽  
M. Gallorini ◽  
C. Birattari ◽  
F. Groppi ◽  
L. Magon ◽  
...  
Keyword(s):  
Specific Activity ◽  
High Specific Activity ◽  
No Carrier Added

scholarly journals Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups

2019 ◽  
Vol 26 (11) ◽  
pp. R627-R652 ◽  
Author(s):  
David Taïeb ◽  
Abhishek Jha ◽  
Giorgio Treglia ◽  
Karel Pacak
Keyword(s):  
Radionuclide Therapy ◽  
Clinical Symptoms ◽  
Specific Activity ◽  
High Specific Activity ◽  
Fda Approval ◽  
Treatment Plans ◽  
Genomic Characterization ◽  
Potential Alternative ◽  
Imaging Algorithms ◽  
Systemic Therapies

In recent years, advancement in genetics has profoundly helped to gain a more comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and paragangliomas (PPGLs). Newly discovered molecular targets, particularly those that target cell membranes or signaling pathways have helped move nuclear medicine in the forefront of PPGL precision medicine. This is mainly based on the introduction and increasing experience of various PET radiopharmaceuticals across PPGL genotypes quickly followed by implementation of novel radiotherapies and revised imaging algorithms. Particularly, 68Ga-labeled-SSAs have shown excellent results in the diagnosis and staging of PPGLs and in selecting patients for PRRT as a potential alternative to 123/131I-MIBG theranostics. PRRT using 90Y/177Lu-DOTA-SSAs has shown promise for treatment of PPGLs with improvement of clinical symptoms and/or disease control. However, more well-designed prospective studies are required to confirm these findings, in order to fully exploit PRRT’s antitumoral properties to obtain the final FDA approval. Such an approval has recently been obtained for high‐specific-activity 131I-MIBG for inoperable/metastatic PPGL. The increasing experience and encouraging preliminary results of these radiotherapeutic approaches in PPGLs now raises an important question of how to further integrate them into PPGL management (e.g. monotherapy or in combination with other systemic therapies), carefully taking into account the PPGLs locations, genotypes, and growth rate. Thus, targeted radionuclide therapy (TRT) should preferably be performed at specialized centers with an experienced interdisciplinary team. Future perspectives include the introduction of dosimetry and biomarkers for therapeutic responses for more individualized treatment plans, α-emitting isotopes, and the combination of TRT with other systemic therapies.

scholarly journals Recovery of high specific activity molybdenum-99 from accelerator-induced fission on low-enriched uranium for technetium-99m generators

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
M. Alex Brown ◽  
Nathan Johnson ◽  
Artem V. Gelis ◽  
Milan Stika ◽  
Anna G. Servis ◽  
...  
Keyword(s):  
Specific Activity ◽  
High Specific Activity ◽  
Fission Products ◽  
Uranyl Sulfate ◽  
New Process ◽  
Extraction Scheme ◽  
Induced Fission ◽  
Enriched Uranium ◽  
No Carrier Added ◽  
Final Purification

AbstractA new process was developed to recover high specific activity (no carrier added) 99Mo from electron-accelerator irradiated U3O8 or uranyl sulfate targets. The process leverages a novel solvent extraction scheme to recover Mo using di(2-ethylhexyl) phosphoric acid following uranium and transuranics removal with tri-n-butyl phosphate. An anion-exchange concentration column step provides a final purification, generating pure 99Mo intended for making 99Mo/99mTc generators. The process was demonstrated with irradiated uranium targets resulting in more than 95% 99Mo recovery and without presence of fission products or actinides in the product.

Sign in / Sign up

Export Citation Format

Share Document